Navigation Links
BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis
Date:3/16/2009

EXTON, Pa., March 16 /PRNewswire/ -- BioTrends Research Group, Inc. has been covering the biologics market for Psoriasis and RA through its TreatmentTrends(TM) series which are syndicated primary research reports based on self reported survey data collected from Dermatologists and Rheumatologists. The company is now expanding these offerings in the form of ChartTrends(TM) reports which aim to compare self-reported treatment patterns with actual patient level data.

The ChartTrends(TM) reports will each offer comprehensive insight into the management and use of biologics used in the treatment of Rheumatoid Arthritis (RA) and Psoriasis. Each report is derived from analysis of actual patient chart data and laboratory results collected from over 1,000 RA and Psoriasis patients currently being treated with biologics. The retrospective audit captures a wide range of patient demographic data, the range of dose variability, co-morbidities, concomitant medications, and laboratory values for the past year. Medication changes and actions taken during office visits are highlighted to understand the triggers for therapy initiation and adjustment. The final report also compares the self-reported practice patterns with actual patient records in order identify gaps in care.

These studies are being undertaken to understand the treatment algorithm for biologic initiation, how each of the biologic brands is typically used, what triggers brand switching, and what patient characteristics (age, co-morbidities, insurance type) influence treatment decisions. Additionally, the study will assess familiarity and interest in several late stage biologics in development (Roche's ACTEMRA, Centocor's SIMPONI, and UCB's CIMZIA in RA and Centocor's STELARA and Abbott's ABT-874 in Psoriasis). BioTrends, which has been offering ChartTrends(TM) reports since 2005, plans to publish the findings in June.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
2. As SEIU Prepares Hostile Takeover of United Healthcare Workers, Surveillance of Local Union Office Ends in Assault by Off-Duty Police Officer
3. SCAIs Annual Fall Fellows Course Prepares New Interventional Cardiologists to Work in the Field
4. Irvine Pharmaceutical Services Enhances Staff, Prepares for Innovative Expansion
5. CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS
6. Gilbert Hospital Prepares for Flu Season
7. American Red Cross Prepares for Tropical Storm Fay in Florida
8. New Anti-Cellulite Treatment Prepares Women for Falls Short Skirts
9. New Anti-Cellulite Treatment Prepares Women for Warmer Weather and Beyond
10. First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch
11. OrthoSynetics(TM) Expands Sales Team; Prepares to Grow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... ... for qualifying into the Senior International Elite division on February 12th. Ms. ... Around divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida ...
(Date:2/23/2017)... ... 2017 , ... The 89th Academy Awards will be celebrated this weekend, which ... Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to ... the Center for American Progress (CAP), for its report, Lessons From State Performance on ...
(Date:2/23/2017)... ... ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be appearing ... which will begin airing on February 24, 2017. The show chronicles the weight loss ... television series, “Here Comes Honey Boo Boo.” The earlier series from TLC lasted for ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... it will soon begin franchising throughout the U.S. starting this spring. Current Meditation ... the practice of meditation mainstream. Current Meditation will be the first meditation concept ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market ... companies have joined forces, resulting in the founding of Pharma To ... Pharma To Market are pleased to announce their expansion into ... in Singapore . The company are delighted to ... Co-Director of the Singapore based entity. Joelle ...
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... STOCKHOLM , Feb 24, 2017 ... Nomination Committee,s proposal for a new Board of Directors ... Meeting. The 2016-2017 Nomination Committee comprises representatives of the ... third quarter of 2016 who have accepted a seat ... Board. The composition of the 2016-2017 Nomination Committee was ...
Breaking Medicine Technology: